Biosimilar Prescribing Habits in the VA & Academic Settings

Conclusion

The uptake of infliximab biosimilars has been slow at an academic medical center compared with a nearby VAMC, where financial savings are realized by the institution from biosimilar use. Slow adoption of biosimilar medications may impact the rates of decline in costs.

Refer to the full study for all source material.

Excerpted and adapted from:

Baker JF, Leonard CE, Lo Re, V III, et al. Biosimilar uptake in academic and Veterans Health Administration settings: Influence of institutional incentives. Arthritis Rheumatol. 2020 Jul;72(7).

The use of biosimilars for rheumatology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

Marching to the Biosimilar Beat: Questions on Rollout Remain

Biosimilars Debate Heats up over Cost Savings, Safety Concerns

The Biosimilars Debate Heats Up: Potential cost savings weighed against patient health & safety

Related Articles